Objective: To evaluate the quality of sleep and its relationship with disease activity in patients with spondyloarthritis (SpA).
Methodology: Observational, cross-sectional study, in patients of 18 to 65 years of age with a diagnosis of SpA. The Pittsburgh Sleep Quality Index (PSQI) questionnaire was used to measure sleep quality, and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP), Disease Activity in PSoriatic Arthritis (DAPSA) instruments were used to assess disease activity.
Results: 72 were evaluated with SpA. The overall median age was 42 (IQ 33.75 – 56.25), the mean sleep quality measured by PSQI was 9.15 ± 4.11. Scores 8 and 9 presenting more frequently with 10 subjects each, followed by score 10, present in 9 individuals. 59 patients with SpA were found to have a PSQI score>5 or poor sleep quality. A significant association was observed for sleep quality measured by PSQI, and disease activity assessed by BASDAI (r 0.530; P<0.001), ASDAS-CRP (r 0.533; P<0.001), DAPSA (r 0.368; P=0.002), VGP (r 0.478; P<0.001), VGM (r 0.382; P=0.001), VAS (r 0.522; P<0.001), SJC/66 (r 0.286; P=0.019), ESR (r -0.363; P =0.021). An association was observed between the use of antidepressants and gabapentinoids with sleep quality by PSQI, showing r 0.30; P=0.005, and r 0.25; P=0.029, respectively.
Conclusion: In patients with SpA, poor sleep quality is an independent factor of greater disease activity.
